Clinical trial
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib…
NCT05704049 · Sanofi, Industry · Active, not recruiting
Key facts
| NCT number | NCT05704049 |
|---|---|
| Title | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma |
| Official title | A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) |
| Acronym | IZALCO |
| Lead sponsor | Sanofi, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed/Refractory Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast, Acetaminophen, Diphenhydramine, Methylprednisolone |
| Enrollment | 118 |
| Start date | Apr 5, 2023 |
| Primary completion | Dec 22, 2025 |
| Completion | May 12, 2028 |
| First posted | Jan 30, 2023 |
| Last update posted | Dec 29, 2025 |
| Countries | Australia, Brazil, China, Czechia, Greece, Japan, Portugal |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: